(-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid modulating activity
被引:141
作者:
Lohray, BB
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Lohray, BB
Lohray, VB
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Lohray, VB
Bajji, AC
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Bajji, AC
Kalchar, S
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Kalchar, S
Poondra, RR
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Poondra, RR
Padakanti, S
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Padakanti, S
Chakrabarti, R
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Chakrabarti, R
Vikramadithyan, RK
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Vikramadithyan, RK
Misra, P
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Misra, P
Juluri, S
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Juluri, S
Mamidi, NVSR
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Mamidi, NVSR
Rajagopalan, R
论文数: 0引用数: 0
h-index: 0
机构:Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
Rajagopalan, R
机构:
[1] Dr Reddys Res Fdn, Discovery Synth, Hyderabad 500016, Andhra Pradesh, India
[2] Dr Reddys Res Fdn, Discovery Biol, Hyderabad 500016, Andhra Pradesh, India
(-)DRF 2725 (6) is a phenoxazine analogue of phenyl propanoic acid. Compound 6 showed interesting dual activation of PPAR alpha and PPAR gamma. In insulin resistant db/db mice, 6 showed better reduction of plasma glucose and triglyceride levels as compared to rosiglitazone. Compound 6 has also shown good oral bioavailability and impressive pharmacokinetic characteristics. Our study indicates that 6 has great potential as a drug for diabetes and dyslipidemia.